CSE: AIML | OTCQB: AIMLF | FWB: 42FB
AI/ML Innovations Inc. (AIML) announced it had formed a strategic partnership with Movesense Ltd. (a wearable medical device manufacturer based in Finland) under which Movesense has become a designated partner for the supply of wearable ECG hardware to be used by NeuralCloud Solutions Inc. (the AIML subsidiary). The partnership will allow for the creation of bundled cardiac monitoring solutions for wearable ECG hardware and AI-based analytical capabilities.
The partnership places AIML in a better position to offer integrated AI-based and device-based cardiac monitoring solutions for clinical, research, wellness and performance markets, thereby further solidifying AIML’s plan to embed AI-based solutions into the workflows of cardiac monitoring professionals.
What Was Announced
NeuralCloud will combine Movesense’s wearable single-lead ECG sensor with their proprietary AI software stacks:
• MaxYieldTM : the AI engine responsible for the denoising of the ECG signal, PQRST wave label identification and machine readable interval identification;
• CardioYieldTM : structured Holter-style ECG review and reporting workflows;
• Insight360TM : no-code, drag-and-drop dashboard for ECG visualization and customizable reporting.
By combining Movesense’s wearable ECG hardware with NeuralCloud’s AI-driven analytical capabilities, AIML is moving beyond offering either standalone software solutions or hardware solutions towards creating complete cardiac monitoring solutions.
Why This Collaboration Is Important
Movesense offers a well-proven, programmable and low-cost wearable ECG hardware foundation for single-lead medical devices, typically worn as a chest strap or body-worn. Combining Movesense wearable ECG hardware with NeuralCloud’s AI-driven analytical capabilities, AIML is able to move beyond the offerings of standalone software or hardware towards a completely integrated cardiac monitoring solution.
The combination of wearable ECG hardware and AI-driven analytical capabilities enable:
• End-to-end ECG workflows from data capture to clinical-style reporting;
• Faster deployments for partners wishing to implement turn-key cardiac monitoring solutions;
• Greater control over data quality, interoperability and workflow design.
“This partnership strengthens our operational and commercial flexibility,” said Erik Suokas, Chief Operating Officer of AI/ML Innovations. “Movesense provides a proven, scalable device platform that allows us to bundle hardware and AI software into unified offerings.
“Movesense was built to enable flexible, high-quality ECG acquisition across a wide range of applications,” said Jussi Kaasinen, CEO of Movesense. “Partnering with NeuralCloud allows our wearable devices to be paired with advanced AI-driven analysis and reporting.”
Pathway to Holter-Style Monitoring
One of the main strategic implications of this collaboration is the ability to address areas traditionally served by higher-cost Holter monitoring systems. By combining scalable single-lead wearable ECG sensors with AI-driven signal processing, labeling and reporting, NeuralCloud is looking to provide cost-effective alternatives that can complement and/or potentially replace traditional Holter workflows.
CardioYieldTM enables structured Holter-style analysis and MaxYieldTM ensures signal quality and labeling of the ECG waveform consistent with clinical review standards. This presents a pathway to expand the use of extended ECG monitoring using more accessible hardware while maintaining alignment with regulatory and clinical standards.
Expansion of Market
Bundled ECG offerings serve several end-markets:
• Clinical and regulated healthcare environments, where structured ECG reporting and workflow integration are necessary;
• Research and performance monitoring, including sports science and applied physiology;
• Wellness and preventive health, supported by Insight360TM’s configurable, no-code reporting tools.
Movesense’s presence in both medical and non-medical device formats allows NeuralCloud to develop solutions for both regulated and unregulated environments without fragmenting its software stack.
Alignment of the Collaboration with AIML’s Strategy
For AIML, the collaboration aligns with a broader strategy to embed AI-powered cardiac intelligence directly into real world workflows. By packaging hardware and software into a unified solution, AIML strengthens its go-to-market position, increases commercial flexibility and decreases dependence on third party hardware ecosystems.
Management emphasized the partnership will lead to faster deployments, greater access to new markets and more competitive pricing for solutions in all three use cases (wellness, monitoring and clinical).
Market Context and Ownership Structure
As of January 2026, AIML shares are trading at approximately CAD $0.035, or a market capitalization of about CAD $6.6 million.
The trading range of AIML shares over the last year spans approximately CAD $0.03 to CAD $0.18. AIML shares are currently trading at the bottom of this range. Prior to 2025, AIML shares traded at levels significantly above this level due to commercial deployments and term sheet agreements related to CardioYieldTM and Holter-style analysis platforms.
From a capital structure perspective, AIML has approximately 253.9 million shares outstanding, 16 million options and 190.7 million warrants, for a fully diluted share count of approximately 460.6 million. This information is relevant to evaluate AIML’s valuation, optionality and the potential for future commercialization success.
Conclusion
The NeuralCloud-Movesense collaboration represents a significant advancement in AIML (AIML | OTCQB: AIMLF | FWB: 42FB)’s transition from an AI analytics provider to a full-stack, device-enabled cardiac monitoring provider. By combining wearable ECG hardware with proprietary AI software, AIML is positioning itself to play a more direct role in scalable, cost-efficient ECG monitoring markets, including those that have historically utilized Holter systems.
Whether or not future commercial success occurs, the collaboration enhances AIML’s product portfolio, expands its addressable markets and reaffirms AIML’s commitment to delivering comprehensive, AI-based cardiac monitoring solutions versus providing stand-alone software solutions.
Marc has been involved in the Stock Market Media Industry for the last +5 years. After obtaining a college degree in engineering in France, he moved to Canada, where he created Money,eh?, a personal finance website.
